Repository logo
Log In
  1. Home
  2. Unibas
  3. Publications
  4. Rapamycin passes the torch: a new generation of mTOR inhibitors
 
  • Details

Rapamycin passes the torch: a new generation of mTOR inhibitors

Date Issued
2011-01-01
Author(s)
Benjamin, D.
Colombi, M.
Moroni, C.  
Hall, M. N.  
DOI
10.1038/nrd3531
Abstract
Mammalian target of rapamycin (mTOR) is an atypical protein kinase that controls growth and metabolism in response to nutrients, growth factors and cellular energy levels, and it is frequently dysregulated in cancer and metabolic disorders. Rapamycin is an allosteric inhibitor of mTOR, and was approved as an immuno-suppressant in 1999. In recent years, interest has focused on its potential as an anticancer drug. However, the performance of rapamycin and its analogues (rapalogues) has been undistinguished despite isolated successes in subsets of cancer, suggesting that the full therapeutic potential of targeting mTOR has yet to be exploited. A new generation of ATP-competitive inhibitors that directly target the mTOR catalytic site display potent and comprehensive mTOR inhibition and are in early clinical trials.
File(s)
Loading...
Thumbnail Image
Name

20130111145229_50f0191d9ecf8.pdf

Size

739.36 KB

Format

Adobe PDF

Checksum

(MD5):f65b1c1a8320d477b596c11392371b83

University of Basel

edoc
Open Access Repository University of Basel

  • About edoc
  • About Open Access at the University of Basel
  • edoc Policy

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement